Responses to therapy
Response . | After CHOP, n (%) . | After CHOP + tositumomab/iodine I 131 tositumomab,* n (%) . |
|---|---|---|
| Complete remission | 24 (27) | 49 (54) |
| Complete remission, unconfirmed | 11 (12) | 11 (12) |
| Partial remission | 44 (49) | 21 (23) |
| Stable disease | 2 (2) | 2 (2)* |
| Not evaluable† | 9 (10) | 7 (8) |
| Total | 90 (100) | 90 (100) |
Response . | After CHOP, n (%) . | After CHOP + tositumomab/iodine I 131 tositumomab,* n (%) . |
|---|---|---|
| Complete remission | 24 (27) | 49 (54) |
| Complete remission, unconfirmed | 11 (12) | 11 (12) |
| Partial remission | 44 (49) | 21 (23) |
| Stable disease | 2 (2) | 2 (2)* |
| Not evaluable† | 9 (10) | 7 (8) |
| Total | 90 (100) | 90 (100) |
Patients who did not achieve a PR, CRu, or CR with CHOP were not eligible to receive tositumomab/iodine I 131 tositumomab.
Incomplete restaging (CT scans, bone marrow [BM] biopsies, etc) was performed on 9 patients after completion of CHOP, rendering them inevaluable for response assessment. Two of these 9 patients had complete restaging after completion of antibody therapy, but 7 remained inevaluable for response after completion of the entire program.